[{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Irofulven","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hydroxyureamethylacylfulvene","moa":"DNA","graph1":"Oncology","graph2":"Preclinical","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"LP-300","moa":"ALK","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Lantern Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Hydroxyureamethylacylfulvene","moa":"DNA","graph1":"Oncology","graph2":"Preclinical","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Lantern Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Lantern Pharma \/ Lantern Pharma"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Lantern Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Hydroxyureamethylacylfulvene","moa":"DNA","graph1":"Oncology","graph2":"Preclinical","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Lantern Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Lantern Pharma \/ Lantern Pharma"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Lantern Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Hydroxyureamethylacylfulvene","moa":"DNA Alkylation","graph1":"Oncology","graph2":"Preclinical","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Lantern Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Lantern Pharma \/ Lantern Pharma"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Allarity Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Lantern Pharma \/ Lantern Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Lantern Pharma"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Irofulven","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Irofulven","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Expanded Collaboration","leadProduct":"Irofulven","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Lantern Pharma \/ National Cancer Institute"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"The Danish Cancer Society Research Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lantern Pharma \/ The Danish Cancer Society Research Center","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ The Danish Cancer Society Research Center"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Irofulven","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"The Greehey Children's Cancer Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Irofulven","moa":"PTGR1","graph1":"Oncology","graph2":"Preclinical","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ The Greehey Children's Cancer Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"Lantern Pharma \/ The Greehey Children's Cancer Research Institute"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dimesna","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"LP-184","moa":"DNA synthesis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"LP-184","moa":"DNA synthesis","graph1":"Oncology","graph2":"Preclinical","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"LP-184","moa":"DNA synthesis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"LP-184","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"LP-184","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"LP-284","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"LP-284","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"LP-184","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"TTC Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"TTC-352","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lantern Pharma \/ Lantern Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Lantern Pharma \/ Lantern Pharma"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Irofulven","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"TTC Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"TTC-352","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lantern Pharma \/ TTC Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Lantern Pharma \/ TTC Oncology"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"LP-284","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Reprocell","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Dimesna","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Reprocell","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Reprocell"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Bielefeld University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Cryptophycin Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Bielefeld University","highestDevelopmentStatusID":"2","companyTruncated":"Lantern Pharma \/ Bielefeld University"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"LP-184","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"LP-184","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"LP-284","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"LP-184","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"LP-284","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"LP-284","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Oregon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"XCE853","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Oregon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lantern Pharma \/ Oregon Therapeutics"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"LP-184","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Irofulven","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lantern Pharma \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Lantern Pharma
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
